Have You Been Diagnosed with Parkinson's Disease in the Past Two Years?

If you or someone you love has recently been diagnosed with Parkinson's disease, we invite you to learn about a path that may delay the development of Parkinson’s disease symptoms.
See if you are eligible

What is the Luma Study?

The LUMA Study is a research study evaluating the safety and efficacy of a study drug compared to a placebo to see if it may delay the progression of Parkinson's disease symptoms in people who are in the early stages of their condition. It is thought that investigational breakthrough therapies, such as the study drug, may be most effective in the early stages of the disease. Participating in a research study before receiving other treatment may be a good option for you.

Targeting the Root of Parkinson's
The investigational drug in the LUMA Study is an LRRK2 inhibitor. This means it works by targeting the LRRK2 gene, which is often overactive in people with Parkinson's disease. By reducing the activity of this gene, the drug may help protect brain cells and slow the progression of the disease.
A New Approach to Treatment
Unlike current Parkinson's medications, which mainly manage symptoms, the investigational drug in the LUMA Study aims to modify the course of the disease itself. This offers hope for a new approach to Parkinson's therapy that could potentially delay the onset of debilitating symptoms and improve the quality of life for those living with the disease.
Addressing Untreated Parkinson's
The LUMA Study is specifically for people who have been diagnosed with Parkinson's within the past two years and have not yet started taking Parkinson's drugs. This focus on early intervention is key, as research suggests that early treatment may be more effective in slowing the progression of the disease.

Can I Take Part in the Study?

Father and his son looking at the camera

 The Luma Study is currently enrolling.

 SC3 Research Group - PASADENA, CA

You may be eligible to participate in the LUMA Study if you:*

  • Are 30-80 years old

  • Were diagnosed with Parkinson’s disease within the last 2 years and were at least 30 years old when you were diagnosed

  • Have never been treated for Parkinson's disease

 
*The study doctor(s) and team can meet with you to discuss further details and questions you may have about the study.

Why Is This Study Important

There is an urgent need for safe and effective treatments that delay or halt the progression of Parkinson's disease. The LUMA Study seeks to address this critical need by evaluating a novel investigational drug designed to target the underlying causes of Parkinson's rather than just managing its symptoms.

By participating in the LUMA Study, you have the opportunity to contribute to groundbreaking research that could potentially lead to a new options for early-stage Parkinson's. This study may provide valuable insights into the potential of LRRK2 inhibitors, a class of drugs that hold promise in slowing the progression of the disease.

Luma_Study_Logo
Cream Black Illustrated Guidebook For UGC Content Creators Wattpad Book Cover (1)

Download Study Brochure

Learn more about the Luma Study, how you can help, and what's in it for you.
You'll also get personalized assistance from the local study team on how you can potentially benefit from the study.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Why you should participate

Access to Parkinson's study treatment
Regular monitoring of your Parkinson’s disease and overall health by physicians who specialize in Parkinson’s disease
The opportunity to help advance the treatment of Parkinson's disease.
Reimbursement for transportation and rideshare to attend study visits, as needed

If you decide to join this study, your health and safety will carefully be monitored by specialists, and your participation will help doctors evaluate the study drugs to measure their effectiveness. 

Frequently Asked Questions (FAQs)

Why is the LUMA Study being conducted?

The purpose of the LUMA Study is to evaluate the safety and efficacy of an investigational drug, as compared to a placebo, to see if it may delay the progression of Parkinson’s disease in eligible patients who are in the early stage of their condition. A placebo is a substance that looks like the investigational drug but does not have active drug. 

Since the LUMA Study is for people with early-stage Parkinson’s, the study may determine whether slowing down LRRK2 protein buildup early on may reduce or delay the need for other approved Parkinson’s medications.

How does the study drug work?
The investigational drug is an LRRK2 (leucine-rich repeat kinase 2) inhibitor, meaning the investigational drug may inhibit, or slow down, the LRRK2 gene. The LRRK2 gene is highly active in people who both do and don’t have an LRRK2 mutation. In Parkinson’s disease, the LRRK2 gene functions abnormally,1 which may cause LRRK2 proteins to build up in neurons and lead to Parkinson’s symptoms.2 Since the LUMA Study is being done in people with early-stage Parkinson’s, the study may also determine whether slowing down LRRK2 buildup early on may reduce or delay the need for other Parkinson’s medications.
How do I decide if this research study is right for me?

Deciding to participate in a research study is an important and personal decision. Before you agree to participate, the study team will review all aspects of the research study with you, and if you wish, your loved one. You will be given a document called an Informed Consent Form that provides, in writing, the research study's purpose, medical measurements that will be done, procedures, potential benefits, risks, and precautions. You will have the opportunity to ask questions and are encouraged to speak with family and your own physician to decide if taking part is right for you.

Additionally, your participation in the study is completely voluntary. You may withdraw from the study at any time, for any reason, without impact to your regular medical care.

Will I be paid for taking part in the study?
Study-related medical care and study medication will be provided at no cost. You may be compensated for some of your transportation and other costs related to the study. The study staff can provide you with more information about this.
Is there a placebo in this study?

Yes. There is a 1 in 2 chance of receiving a placebo during this study. A placebo is a substance that looks like the investigational drug but contains no active component. A placebo helps to differentiate any changes seen during the study and determine whether they are due to the study drug alone and not another reason.

There is also a 1 in 2 chance that you will receive the investigational drug. Your treatment group will be assigned at random (by chance), so neither you nor the study team will know which one you are receiving. However, in case of an emergency, the study doctor can quickly find out.

What will happen to my personal information?
The information you provide will be kept confidential in a secure database and used to evaluate your qualification for this study only. With your permission and if you meet the prescreening criteria, we will forward your contact information and online prescreener answers to the study site you selected. If you do not meet the prescreening criteria, all information regarding your identification will be deleted from our database, unless you authorize us to contact you in the future. Your information is not shared with any third-party organization for any separate use or shared with anyone who is not directly associated with this clinical research study without your permission (except as required by law) or as set forth in the informed consent. You can read or download a copy of our full data privacy notice.
Does my doctor need to give me permission to participate?
No, your doctor does not have to give you permission to participate. However, feel free to talk to your doctor about participating in the study. With your permission, the study doctor will keep your regular doctor updated about your condition during the study.
Can I withdraw from the study after I have started?
Yes, your participation in any research study is completely voluntary. If you decide to participate in a research study, you are always free to withdraw at any time, for any reason, without any penalty or effect on your future medical care. You should talk to your study doctor about leaving the study so that a final evaluation can be scheduled.

You can advance Parkinson's research

The Luma Study Is Currently Enrolling
Along with the PD research community, we are committed to finding solutions for everyone affected by Parkinson's disease— the very people who hold the key to the answers. Without participants in research studies, Parkinson's disease research would come to a standstill.
See if you pre-qualify

Clinical research site location near you

SC3 Research Group, Inc. has a clinical research site location at Pasadena. Travel reimbursement may be provided

SC3 Research Group, Inc - Pasadena

Phone: (626) 250-2070

Contact: Roxanne Cabading

Email : roxanne.cabading@neurosearch-usa.com

Address: 50 BELLEFONTAINE ST., STE 203, PASADENA, CA 91105